The Role of Appellist in the Development of a Drug for Eye Infections

Adam Steller: The rates of ROV seem to be higher in an approved Novartis medicine with a different biological target and the treats of different disease. Appellist has not found a single cause for these cases yet, but they are still looking. And so, you know, when I talk to analysts about this, yes, they need to come up with some kind of risk mitigation plan that will help people to mitigate the risk," he says.